HelicoТer - OPTIMAL SOLUTION
for patients with H. pylori infection, gastritis, stomach ulcer and duodenum ulcer
REDUCES THE QUANTITY OF H. PYLORI TO A SAFE LEVEL
EXCLUDES NEGATIVE CONSEQUENCES OF ERADICATION THERAPY
PRESERVES HEALTHY MICROFLORA BALANCE IN STOMACH
Helicobacter pylori (H. pylori) is a small spiral-shaped gram-negative bacterium. It infects more than 60% of the world’s population, but for some people it may be harmless during some (sometimes long) period of life. The uniqueness of this microorganism lies in its ability to dwell in one of the most aggressive environments of the body – in the acidic environment of the stomach.
Barry Marshall, Professor of Clinical Microbiology at the University of Western Australia first proved that gastric ulcer is in most cases caused by H. pylori, for which he received the 2005 Nobel Prize in Medicine and Physiology.
For many years, the only way to treat diseases caused by H. pylori was eradication – that is the complete removal of this bacterium from the body using antibiotics. But later it turned out that the complete eradication of Helicobacter pylori can lead to serious diseases: gastroesophageal reflux disease, asthma and esophageal adenocarcinoma.
How can we reduce the number of Helicobacter PYLORI but
at the same time not increase the risk of serious diseases?
TAKING HelicoТer WE GET
- comfortable reduction in the amount of H. pylori
- no risk of dangerous complications
- exacerbation prevention in patients with gastritis, ulcers and duodenitis
HelicoTer is a unique remedy with proven efficacy and unrivaled safety for patients with Helicobacter pylori infection. HelicoTer contains a specially developed ingredient non-viable Lactobacillus reuteri, which has a specific anti-helicobacter effect.
HOW DOES IT WORK?
HelicoTer helps to reduce the bacterial burden of H. pylori in the stomach in a targeted manner. It works by forming coaggregates with H. pylori due to its molecular shape, which is a bit like velcro.
The molecules on the surface of Lactobacillus reuteri coincide in size with the structures on the surface of H. pylori. Coaggregation depends only on the mechanical binding of these structures. After coaggregation, it is eliminated from the body through the digestive tract, thereby lowering the level of H. pylori.
The result is a necessary reduction in the level of Helicobacter pylori, which helps prevent the recurrence of chronic diseases of the gastrointestinal tract, and also prevents the appearance of diseases of the stomach and duodenum.
HelicoTer is recommended for patients with chronic gastrointestinal diseases, which risk factor is the bacterium Helicobacter pylori: erosive gastritis, gastric ulcer and duodenal ulcer.
HelicoTer is taken with meals.
Adults – 1 capsule 1 time per day. The dose may be increased up to 2 capsules per day on the recommendation of a doctor.
Children over 6 years old – 1 capsule 1 time per day with meals.
The duration of treatment is 4 weeks. Consultation with a doctor is recommended before use.
1. Mishra S. Is Helicobacter pylori good or bad? Eur. J. Clin. Microbiol. Infect. Dis. 2013 Mar; 32 (3) : 301-4.
2. Bravo D., Hoare A., Soto C., Valenzuela M, Quest A. Helicobacter pylori in human health and disease: Mechanisms for local gastric and systemic effects. World J. Gastroenterol. 2018 Jul 28; 24 (28): 3071–3089.
3. Abadi A. Helicobacter pylori: A Beneficial Gastric Pathogen? Front. Med. (Lausanne). 2014; 1: 26.
DISTRIBUTORS
